

***Effective November 1, 2023, refer to CMS Manual 100-02, Chapter 16-General Exclusions from Coverage for services included in this policy.***



**BlueCross BlueShield  
of Alabama**

---

**Name of Blue Advantage Policy:**  
**Plugs for Anal Fistula Repair**

Policy #: 399

Latest Review Date: November 2022

Category: Surgical

**ARCHIVED EFFECTIVE 11/1/2023**

---

**BACKGROUND:**

*Blue Advantage medical policy does not conflict with Local Coverage Determinations (LCDs), Local Medical Review Policies (LMRPs) or National Coverage Determinations (NCDs) or with coverage provisions in Medicare manuals, instructions or operational policy letters. In order to be covered by Blue Advantage the service shall be reasonable and necessary under Title XVIII of the Social Security Act, Section 1862(a)(1)(A). The service is considered reasonable and necessary if it is determined that the service is:*

1. *Safe and effective;*
2. *Not experimental or investigational\*;*
3. *Appropriate, including duration and frequency that is considered appropriate for the service, in terms of whether it is:*
  - *Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member;*
  - *Furnished in a setting appropriate to the patient's medical needs and condition;*
  - *Ordered and furnished by qualified personnel;*
  - *One that meets, but does not exceed, the patient's medical need; and*
  - *At least as beneficial as an existing and available medically appropriate alternative.*

*\*Routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000 which meet the requirements of the Clinical Trials NCD are considered reasonable and necessary by Medicare. Providers should bill **Original Medicare** for covered services that are related to **clinical trials** that meet Medicare requirements (Refer to Medicare National Coverage Determinations Manual, Chapter 1, Section 310 and Medicare Claims Processing Manual Chapter 32, Sections 69.0-69.11).*

## **POLICY:**

### **For dates of service on or after March 24, 2020:**

**Blue Advantage** will treat **biosynthetic fistula plugs**, including plugs made of porcine small intestine submucosa or of synthetic material as a **non-covered** benefit and as **investigational** for the repair of anal fistulas.

---

**Effective for dates of service on or after February 26, 2018 through March 23, 2020, refer to LCD L36954**

---

### **Effective for dates of service prior to February 26, 2018:**

**Blue Advantage** will treat **biosynthetic fistula plugs**, including plugs made of porcine small intestine submucosa or of synthetic material as a **non-covered** benefit and as **investigational** for the repair of anal fistulas.

*Blue Advantage does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. Blue Advantage administers benefits based on the members' contract and medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.*

## **DESCRIPTION OF PROCEDURE OR SERVICE:**

Anal fistula plugs (AFPs) are biosynthetic devices used to promote healing and prevent the recurrence of anal fistulas (fistula-in-ano). They are proposed as an alternative to procedures including fistulotomy, endorectal advancement flaps, seton drain placement, and use of fibrin glue in the treatment of anal fistulas.

### **Anal Fistulas**

An anal fistula is an abnormal communication between the interior of the anal canal or rectum and the skin surface. Rarer forms may communicate with the vagina or other pelvic structures, including the bowel. Most fistulas begin as anorectal abscesses, which are thought to arise from infection in the glands around the anal canal. When the abscess opens spontaneously into the anal canal (or has been opened surgically), a fistula may occur. Studies have reported that 26% to 37% of cases of perianal abscesses eventually form anal fistulas.

Other causes of fistulas include tuberculosis, cancer, prior radiotherapy, and inflammatory bowel disease. Fistulas may occur singly or in multiples. Symptoms include a purulent discharge and drainage of pus and/or stool near the anus, which can irritate the outer tissues causing itching and discomfort. Pain occurs when fistulas become blocked and abscesses recur. Flatus may also escape from fistulous tract.

The most widely used classification of anal fistulas is the Parks' classification system, which defines anal fistulas by their position relative to the anal sphincter as trans-sphincteric, intersphincteric, suprasphincteric, or extrasphincteric. More simply, anal fistulas are described as low (present distally and not extending up to anorectal sling) or high (extending up to or beyond the ano-rectal sling). The repair of high fistula can be associated with incontinence. Diagnosis may involve fistula probe, anoscopy, fistulography, ultrasound, or magnetic resonance imaging.

## **Treatment**

Treatment is aimed at repairing the fistula without compromising continence.

Surgical treatments for anal fistulas include fistulotomy/fistulectomy, endorectal/anal sliding flaps, ligation of the intersphincteric fistula tract (LIFT) technique, Seton drain, and fibrin glue. Fistulotomy involves a division of the tissue over the fistula and lying open of the fistula tract. Although fistulotomies are widely used for low fistulas, lay-open fistulotomies in high fistulas carries the risk of incontinence. A Seton is a thread placed through the fistula tract for the purpose of draining fistula material and preventing the development of a perianal infection. Draining Setons can control sepsis, but few patients heal after removal of the Seton, and the procedure is poorly tolerated long-term. A "cutting seton" refers to the process of regular tightening of the Seton to encourage the gradual cutting of the sphincteric muscle with subsequent inflammation and fibrosis. Cutting Setons can cause continence disturbances. Endorectal advancement flaps involve the advancement of a full or partial thickness flap of the proximal rectal wall over the internal (rectal) opening of the fistula tract. The LIFT technique involves identifying the intersphincteric plane and then dividing the fistula tract; its use has been reported in small studies, but long-term follow-up is unavailable. Fibrin glue is a combination of fibrinogen, thrombin, and calcium in a matrix, which is injected into the fistula tract. The glue induces clot formation within the tract, which is then closed through overgrowth of new tissue.

## **Fistula Plugs**

Fistula plugs are designed to provide a structure that acts as a scaffold for new tissue growth. The scaffold, which can be derived from animal (e.g., porcine) tissue or a synthetic copolymer fiber, is degraded by hydrolytic or enzymatic pathways as healing progresses. The plug is pulled through the fistula tract and secured at the fistula's proximal opening; the fistula tract is left open at the distal opening to allow drainage. Several fistula plugs have been cleared for marketing by the U.S. Food and Drug Administration (FDA).

A fistula plug derived from autologous cartilage tissue has been investigated in a small (n=10) pilot study.

## **KEY POINTS:**

The most recent literature search was performed for the period through September 21, 2022.

## **Summary of Evidence:**

For individuals who have anal fistula(s) who receive placement of AFP(s), the evidence includes 4 RCTs, a number of comparative and noncomparative nonrandomized studies, and systematic

reviews of these studies. Relevant outcomes are symptoms, change in disease status, morbid events, functional outcomes, and treatment-related morbidity. Two RCTs comparing AFP with surgical flap treatment have reported disparate findings: 1 found significantly higher rates of fistula recurrence with AFP; the other found similar rates of recurrence for AFP and surgical treatment. Another RCT that compared AFP with seton drain removal alone for patients with fistulizing Crohn disease, found no significant difference in healing rates at 12 weeks between groups. An RCT comparing AFP with surgeon's preference reported significantly higher complication rates with AFP. Systematic reviews of AFP repair have demonstrated a wide range of success rates and heterogeneity in study results. Nonrandomized studies have also reported conflicting results. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

### **Practice Guidelines and Position Statements**

#### **American Society of Colon and Rectal Surgeons**

The 2022 practice guideline on the treatment of anorectal abscess, fistula-in-ano, and rectovaginal fistula from the Society provided a strong recommendation based on moderate-quality evidence that anal fistula plug and fibrin glue are relatively ineffective treatments for fistula-in-ano.

#### **National Institute for Health and Care Excellence**

The National Institute for Health and Care Excellence (2019) published an updated guidance on the suturable bioprosthetic plug. The Institute determined that evidence that "evidence on the safety and efficacy of bioprosthetic plug insertion for anal fistula is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent, and audit." Though, it was noted that "the procedure should only be done by a surgeon experienced in managing anal fistulas."

#### **U.S. Preventive Services Task Force Recommendations**

Not applicable.

### **KEY WORDS:**

Biosynthetic fistula plugs, SIS Fistula Plug, modified SIS Fistula Plug, GORE BIO-A Fistula Plug, porcine small intestine submucosa plugs, synthetic fistula plug, suturable bioprosthetic plug, anal fistula plug, fistula plug, LIFT technique, SURGISIS soft Tissue Graft, STRATASIS Urethral Sling

### **APPROVED BY GOVERNING BODIES:**

Several plugs for anal fistula repair have received clearance for marketing from FDA through the 510(k) process and are outlined in Table 1.

**Table 1: Devices for Anal Fistula Repair**

Device	Year	Description	Indication(s)	Predicate Device(s)	FDA Product Code
SIS Fistula Plug (Cook Biotech Inc.)	March 2005	Manufactured from porcine SIS	Repair of anal, rectal, and enterocutaneous fistulas	SURGISIS® Soft Tissue Graft (Cook Biotech Inc.)  STRATASIS® Urethral Sling (Cook Biotech Inc.)	FTM
Surgisis RVP Recto-Vaginal Fistula Plug (Cook Biotech Inc.)	Oct. 2006	Manufactured from porcine SIS  Tapered configuration with a button to provide increased plug retention and improved blockage of the fistula	Reinforce soft tissue for the repair of rectovaginal fistulas	SIS Fistula Plug (Cook Biotech Inc.)	FTM
Surgisis Biodesign Enterocutaneous Fistula Plug (Cook Biotech, Inc.)	Feb. 2009	Manufactured from porcine SIS  Tapered configuration with a flange to provide increased retention of the plug and improved blockage of the fistula	Reinforce soft tissue for the repair of enterocutaneous fistulas	SIS Fistula Plug (Cook Biotech Inc.)	FTM

Gore Bio-A Fistula Plug (W.L. Gore & Associates Inc.)	Mar. 2009	Manufactured from bioabsorbable polyglycolide- co-trimethylene carbonate (PGA:TMC) copolymer  Supplied in a 3- dimensional configuration of a disk with attached tubes	Reinforce soft tissue for the repair of anorectal fistulas	Gore Bioabsorbable Mesh (W.L. Gore & Associates Inc.)  SIS Fistula Plug (Cook Biotech Inc.)	FTL
Biodesign Anal Fistula Plug (Cook Biotech)	May 2016	Manufactured from porcine SIS Additional wash steps have been added in processing	Reinforce soft tissue where a rolled configuration is required, for repair of anal, rectal and enterocutaneous fistulas	SIS Fistula Plug (Cook Biotech)	FTM

FDA: Food and Drug Administration; PGA:TMC: polyglycolide-co-trimethylene carbonate; SIS: small intestinal submucosa.

### **BENEFIT APPLICATION:**

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

### **CURRENT CODING:**

#### **CPT Codes:**

46707	Repair of anorectal fistula with plug (e.g. porcine small intestine mucosa [SIS])
-------	---

### **REFERENCES:**

1. Blom J, Husberg-Sellberg B, Lindelius A, et al. Results of collagen plug occlusion of anal fistula: a multicentre study of 126 patients. *Colorectal Dis.* Aug 2014; 16(8):626-630.

2. Campbell ML, Abboud EC, Dolberg ME, et al. Treatment of refractory perianal fistulas with ligation of the intersphincteric fistula tract: preliminary results. *Am Surg.* Jul 2013; 79(7):723-727.
3. Cheung XC, Fahey T, Rogers AC, et al. Surgical Management of Idiopathic Perianal Fistulas: A Systematic Review and Meta-Analysis. *Dig Surg.* 2021; 38(2): 104-119.
4. Cintron JR, Abcarian H, Chaudhry V, et al. Treatment of fistula-in-ano using a porcine small intestinal submucosa anal fistula plug. *Tech Coloproctol.* Apr 2013; 17(2):187-191.
5. Cirocchi R, Trastulli S, Morelli U, et al. The treatment of anal fistulas with biologically derived products: is innovation better than conventional surgical treatment? An update. *Tech Coloproctol.* Jun 2013; 17(3):259-273.
6. Fisher OM, Raptis DA, Vetter D, et al. An outcome and cost analysis of anal fistula plug insertion vs endorectal advancement flap for complex anal fistulae. *Colorectal Dis.* Jul 2015; 17(7):619-626.
7. Gaertner WB, Burgess PL, Davids JS, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anorectal Abscess, Fistula-in-Ano, and Rectovaginal Fistula. *Dis Colon Rectum.* Aug 01 2022; 65(8): 964-985.
8. Hall JF, Bordeianou L, Hyman N, et al. Outcomes after operations for anal fistula: results of a prospective, multicenter, regional study. *Dis Colon Rectum.* Nov 2014; 57(11):1304-1308.
9. IOM (Institute of Medicine). 2011. Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies Press.
10. Jayne DG, Scholefield J, Tolan D, et al. A Multicenter Randomized Controlled Trial Comparing Safety, Efficacy, and Costeffectiveness of the Surgisis Anal Fistula Plug Versus Surgeon's Preference for Transsphincteric Fistula-in-Ano: The FIAT Trial. *Ann Surg.* Jun 09 2020.
11. Jayne DG, Scholefield J, Tolan D, et al. A Multicenter Randomized Controlled Trial Comparing Safety, Efficacy, and Cost-effectiveness of the Surgisis Anal Fistula Plug Versus Surgeon's Preference for Transsphincteric Fistula-in-Ano: The FIAT Trial. *Ann Surg.* Mar 01 2021; 273(3): 433-441.
12. Leng Q, Jin HY. Anal fistula plug vs mucosa advancement flap in complex fistula-in-ano: a meta-analysis. *World J Gastrointest Surg* Nov 27. 2012; 4(11):256-261.
13. Narang SK, Jones C, Alam NN, et al. Delayed absorbable synthetic plug (GORE(R) BIO-A(R)) for the treatment of fistula-in-ano: a systematic review. *Colorectal Dis.* Jan 2016; 18(1):37-44.
14. Nasser Y, Cassella L, Berns M, et al. The anal fistula plug in Crohn's disease patients with fistula-in-ano: a systematic review. *Colorectal Dis.* Apr 2016;18(4):351-356.
15. National Institute for Health and Care Excellence (NICE). Bioprosthesis plug insertion for anal fistula. Sep 2019. <https://www.nice.org.uk/guidance/ipg662>. Accessed October 7, 2019.
16. National Institute for Health and Care Excellence (NICE). Bioprosthesis plug insertion for anal fistula [IPG662]. September 25, 2019; <https://www.nice.org.uk/guidance/ipg662>. Accessed September 12, 2021.

17. National Institute for Health and Care Excellence (NICE). Bioprosthetic plug insertion for anal fistula [IPG662]. September 25, 2019; <https://www.nice.org.uk/guidance/ipg662>. Accessed September 21, 2022.
18. National Institute for Health and Clinical Excellence (NICE). Closure of anal fistula using a suturable bioprosthetic plug. June 2011. Accessible at [www.nice.org.uk/guidance/IPG410](http://www.nice.org.uk/guidance/IPG410). Accessed September 2017.
19. O’Riordan JM, Datta I, Johnston C et al. A systematic review of the anal fistula plug for patients with Crohn’s and non-Crohn’s related fistula-in-ano. *Dis colon rectum*. Mar 2012; 55(3):351-358.
20. Ozturk E. Treatment of recurrent anal fistula using an autologous cartilage plug: A pilot study. *Tech Coloproctol*. May 2015; 19(5):301-307.
21. Pu YW, Xing CG, Khan I et al. Fistula plug versus conventional surgical treatment for anal fistulas. A system review and meta-analysis. *Saudi Med J*. Sep 2012; 33(9):962-966.
22. Senejoux A, Siproudhis L, Abramowitz L, et al. Fistula Plug in Fistulising Ano-Perineal Crohn's Disease: a Randomised Controlled Trial. *J Crohns Colitis*. Feb 2016; 10(2):141-148.
23. Simpson JA, Banerjea A, Scholefield JH. Management of anal fistula. *BMJ*. 2012; 345:e6705.
24. Stamos MJ, Snyder M, Robb BW, et al. Prospective multicenter study of a synthetic bioabsorbable anal fistula plug to treat cryptoglandular transsphincteric anal fistulas. *Dis Colon Rectum*. Mar 2015; 58(3):344-351.
25. Stewart DB, Sr., Gaertner W, Glasgow S, et al. Clinical Practice Guideline for the management of anal fissures. *Dis Colon Rectum*. Jan 2017;60(1):7-14.
26. Tan KK, Kaur G, Byrne CM, et al. Long-term outcome of the anal fistula plug for anal fistula of cryptoglandular origin. *Colorectal Dis*. Dec 2013; 15(12):1510-1514.
27. Vogel JD, Johnson EK, Morris AM, et al. Clinical practice guideline for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. *Dis Colon Rectum*. Dec 2016; 59(12):1117-1133.
28. Xu Y, Tang W. Comparison of an anal fistula plug and mucosa advancement flap for complex anal fistulas: a meta-analysis. *ANZ J Surg*. Sep 29 2016.

## **POLICY HISTORY:**

Adopted for Blue Advantage, January 2010  
 Available for comment January 26-March 11, 2010  
 Medical Policy Group, January 2012  
 Medical Policy Group, June 2012  
 Medical Policy Group, November 2013  
 Medical Policy Group, October 2014  
 Medical Policy Group, September 2015  
 Medical Policy Group, November 2016  
 Medical Policy Group, November 2017  
 Medical Policy Group, February 2018



Medical Policy Group, April 2020: Reinstated effective March 24, 2020.  
Medical Policy Group, November 2021  
Medical Policy Group, November 2022  
Medical Policy Group, November 2023: Archived effective 11/1/2023.

---

*This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member's plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.*

*This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield's administration of plan contracts.*